Arbutus Biopharma Corporation ABUS
3.72 USD +0.07 (+1.78%)
At closeNov 10, 2026, 4:28 AM EST
3.65 -0.07 -1.88%
Pre-market · Nov 10, 4:28 AM ET
3.59 Day range 3.75
3.50 52-week range 5.45
- YTD
- -22.66%
- 1 year
- -17.33%
News
benzinga.com FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
benzinga.com Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the